Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.

Excluding data on products identified by Clarke et al 2 due to calculation of the duration of marketing by other authors and thus a lack of evaluation of trends, four of the studies identified in the published literature established a decreasing trend in average duration of marketing prior to regulatory action over time. 14 15 33 36 Although the remaining studies did not report trends within their data, each demonstrated a longer duration of marketing prior to regulatory action in comparison with earlier research. 11 12 The duration of marketing for medicinal products that underwent regulatory action between 2012 and 2016 increased over time, demonstrated by the trend line in figure 2 .

also in 47,180 other papers